CytomX Therapeutics (CTMX)
2.69
-0.51 (15.94%)
Upcoming Events
Latest Headlines
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
September 1, 2026 9:07 AM - StreetInsider
FDA grants fast track status to CytomX drug for colorectal cancer
August 27, 2026 8:02 AM - StreetInsider
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
August 27, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.
August 14, 2026 4:12 PM - SEC Filing
Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Kynam Capital Management, LP
August 14, 2026 12:12 PM - SEC Filing
CytomX Therapeutics (CTMX) PT Lowered to $11 at JPMorgan
August 13, 2026 9:08 AM - StreetInsider
CytomX Therapeutics (CTMX) PT Lowered to $14 at Guggenheim
August 10, 2026 7:28 AM - StreetInsider
Form SCHEDULE 13G CytomX Therapeutics, Filed by: STATE STREET CORP
August 7, 2026 9:23 AM - SEC Filing
Form S-8 CytomX Therapeutics,
August 6, 2026 4:32 PM - SEC Filing
CytomX Therapeutics (CTMX) Misses Q2 EPS by 1c
August 6, 2026 4:18 PM - StreetInsider
Form 8-K CytomX Therapeutics, For: Aug 06
August 6, 2026 4:16 PM - SEC Filing
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
August 6, 2026 4:15 PM - Globe NewsWire
Form 10-Q CytomX Therapeutics, For: Jun 30
August 6, 2026 4:08 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Aug 03 Filed by: Carvajal Alejandra
August 5, 2026 7:33 PM - SEC Filing
Form 3 CytomX Therapeutics, For: Aug 03 Filed by: Carvajal Alejandra
August 5, 2026 7:32 PM - SEC Filing
Form SCHEDULE 13G CytomX Therapeutics, Filed by: BANK OF AMERICA CORP /DE/
August 3, 2026 12:05 PM - SEC Filing
CytomX Therapeutics names Alejandra Carvajal as chief legal officer
August 3, 2026 8:00 AM - StreetInsider
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
August 3, 2026 8:00 AM - Globe NewsWire
Form 4 CytomX Therapeutics, For: Jul 24 Filed by: Fuchs Charles S.
July 30, 2026 5:07 PM - SEC Filing
Form 3 CytomX Therapeutics, For: Jul 24 Filed by: Fuchs Charles S.
July 30, 2026 5:06 PM - SEC Filing
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026 8:00 AM - Globe NewsWire
Form SCHEDULE 13G CytomX Therapeutics, Filed by: BlackRock, Inc.
July 27, 2026 4:26 PM - SEC Filing
Form 8-K CytomX Therapeutics, For: Jul 24
July 27, 2026 8:05 AM - SEC Filing
CytomX Therapeutics adds oncologist Charles Fuchs to its board
July 27, 2026 8:00 AM - StreetInsider
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
July 27, 2026 8:00 AM - Globe NewsWire
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Su Zhen
June 22, 2026 4:53 PM - SEC Filing
Form 8-K CytomX Therapeutics, For: Jun 17
June 22, 2026 4:52 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Young Matthew P.
June 22, 2026 4:52 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Mohindru Mani
June 22, 2026 4:50 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Meyers James R
June 22, 2026 4:50 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Gilbert Halley E
June 22, 2026 4:49 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Ashworth Alan
June 22, 2026 4:48 PM - SEC Filing
Form 4 CytomX Therapeutics, For: Jun 17 Filed by: Jones Elaine V
June 22, 2026 4:46 PM - SEC Filing
Full Article List
